GSK Expects Further Profit Growth After Beating Market Views
The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...
GSK beats Q4 earnings estimates, lifts 2031 sales target
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...
GSK Announces £2 Billion Share Buyback as Profit Beats Estimates
GSK Plc announced a share buyback of £2 billion as it saw better than expected profit in the fourth quarter. The share ...
GSK FY24 Core Operating Profit Rises, Turnover Up 7% At CER; Increases 2031 Sales Outlook
GSK (GSK.L, GSK) reported fiscal 2024 profit before tax of 3.5 billion pounds, down 43% at AER, or down 34% at CER from prior year.
FTSE 100 giant GSK eyes more than £40bn in sales by 2031
Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than ...
Insider36m
GSK lifts sales guidance after “excellent” performance in 2024
Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline.
GSK falls Tuesday, underperforms market
GSK PLC closed 24.32% short of its 52-week high of £18.24, which the company achieved on May 16th.
GSK lifts long-term sales outlook on strong Specialty Medicines growth
GSK’s global performance showed strength across key markets. Sales in the United States reached £16.4 billion, up 6% at ...
GSK launches £2bn buyback plan, lifts long-term guidance
GSK today increased its 2031 sales outlook to more than £40 billion, up from £38 billion amid stronger progress in its ...
bovnews13h
GSK’s Unexpected Plunge: What’s Next?
On Monday, GSK plc (GSK) stock saw a decline, ending the day at $34.9 which represents a decrease of $-0.37 or -1.05% from the prior close of $35.27. The stock opened at $34.87 and touched a low of ...
GSK Sales, Core Earnings Expected to Fall -- Earnings Preview
CORE EARNINGS PER SHARE FORECAST: Fourth-quarter core earnings per share is expected to fall to 20.6 pounds from 28.9 pounds the year earlier, according to Visible Alpha. Shares in GSK are 3.6% up ...
GSK Pharma put volume heavy and directionally bearish
Bearish flow noted in GSK (GSK) Pharma with 1,131 puts trading, or 2x expected. Most active are Mar-25 33 puts and Jan-26 35 puts, with total volume in those strikes near 730 contracts. The Put/Call ...